MX2020003034A - Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. - Google Patents

Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.

Info

Publication number
MX2020003034A
MX2020003034A MX2020003034A MX2020003034A MX2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A MX 2020003034 A MX2020003034 A MX 2020003034A
Authority
MX
Mexico
Prior art keywords
antibody
antigen binding
binding fragment
medical application
application therefor
Prior art date
Application number
MX2020003034A
Other languages
English (en)
Inventor
Hua Ying
Weikang Tao
Qiyue Hu
Yifang Wang
Hu Ge
Jinping Shi
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020003034A publication Critical patent/MX2020003034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan un anticuerpo IL-5, un fragmento de unión a antígeno del mismo y una aplicación médica para el mismo. La presente invención comprende un anticuerpo derivado de ratón que contiene una región CDR de anticuerpo IL-5, un anticuerpo quimérico, un anticuerpo humanizado y una composición farmacéutica que comprende dicho anticuerpo IL-5 y dicho fragmento de unión a antígeno del mismo, así como el uso de la composición farmacéutica como una droga.
MX2020003034A 2017-09-29 2018-09-28 Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica. MX2020003034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710906068 2017-09-29
PCT/CN2018/108240 WO2019062831A1 (zh) 2017-09-29 2018-09-28 Il-5抗体、其抗原结合片段及医药用途

Publications (1)

Publication Number Publication Date
MX2020003034A true MX2020003034A (es) 2020-07-22

Family

ID=65900695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003034A MX2020003034A (es) 2017-09-29 2018-09-28 Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.

Country Status (12)

Country Link
US (2) US11365247B2 (es)
EP (1) EP3689906A4 (es)
JP (1) JP7307720B2 (es)
KR (1) KR20200059239A (es)
CN (1) CN111065651B (es)
AU (1) AU2018340557A1 (es)
BR (1) BR112020005766A2 (es)
CA (1) CA3076941A1 (es)
MX (1) MX2020003034A (es)
TW (1) TWI801425B (es)
WO (1) WO2019062831A1 (es)
ZA (1) ZA202001807B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020200099A1 (zh) * 2019-03-29 2020-10-08 江苏恒瑞医药股份有限公司 包含抗il-5抗体的药物组合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU683836B2 (en) 1992-02-06 1997-11-27 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
DE69535319T2 (de) 1994-12-23 2007-07-19 Smithkline Beecham Corp. Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
MXPA04009418A (es) 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
ATE541585T1 (de) 2004-10-28 2012-02-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose.
EP2222709B1 (en) * 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
JP5414535B2 (ja) 2007-12-03 2014-02-12 株式会社アドバンス １本鎖抗体ｓｃＦｖの製造方法
US9505826B2 (en) 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
CN114702594A (zh) 2013-12-20 2022-07-05 豪夫迈·罗氏有限公司 双重特异性抗体
ES2811124T3 (es) 2014-09-08 2021-03-10 Cephalon Inc Uso de reslizumab para tratar el asma eosinofílica moderada a grave
CN116327921A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物

Also Published As

Publication number Publication date
US20200262909A1 (en) 2020-08-20
JP2021502801A (ja) 2021-02-04
US20220356239A1 (en) 2022-11-10
TW201915022A (zh) 2019-04-16
EP3689906A4 (en) 2021-04-07
CN111065651B (zh) 2023-07-14
AU2018340557A1 (en) 2020-04-09
TWI801425B (zh) 2023-05-11
EP3689906A1 (en) 2020-08-05
ZA202001807B (en) 2022-09-28
WO2019062831A1 (zh) 2019-04-04
RU2020112984A (ru) 2021-10-29
CA3076941A1 (en) 2019-04-04
RU2020112984A3 (es) 2021-11-25
BR112020005766A2 (pt) 2020-10-13
KR20200059239A (ko) 2020-05-28
CN111065651A (zh) 2020-04-24
US11365247B2 (en) 2022-06-21
JP7307720B2 (ja) 2023-07-12

Similar Documents

Publication Publication Date Title
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
MX2018008592A (es) Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos.
PH12018501554A1 (en) Ror1 antibody compositions and related methods
EP3505535A4 (en) MONOCLONAL ANTI-PD-1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
EP3604337A4 (en) B7-H3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THE SAME, AND ITS MEDICAL USE
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EP3712170A4 (en) CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
MX2017011432A (es) Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
AU2016319433A8 (en) Anti-EphA4 antibody
MY194084A (en) Interferon beta antibodies and uses thereof
NZ728981A (en) Anti-ceramide antibodies
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.